NFKB1 and metabolic dysfunction-associated steatotic liver disease: As depicted in Figure 8, the elaborated work in this study provides a mechanistic insight into AICAR’s ameliorative effects in NAFLD through disrupting the HGF/NF-κB/SNARK signaling pathway, abrogating mitochondrial dysfunction via Drp1/SIRT2 axis, and relieving ER stress.